

**8th Annual Hereditary Cancer Symposium for Health Care Providers (Hybrid Format)**

**4/4/2025 7:00:00 AM - 4/5/2025 11:30:00 AM**

**Target Audience:**

Professions: Physician (MD or DO), Nurse - RN, Genetic Counselor, Geneticist, Social Worker, Student or Trainee, Nurse - APRN

**Description:**

This Symposium is targeted to inter-professional healthcare providers working with Clinical Cancer Genetics. The event will give attendees the awareness of cancer treatment options and appropriate referrals tailored to genetic testing results. This activity aims to close the gap in knowledge regarding management for patients with certain genetic dispositions.

**Learning Objectives:**

1 Implement guidelines to assess and screen high-risk patients in daily practice.

2 Recognize and document key features associated with potential hereditary cancer predispositions to refer at-risk patients for genetic cancer risk assessment

3 Examine the psychosocial and medical impacts of genetic testing results on the patient with respect to both current and long-term management

4 Differentiate the utility of various genetic testing modalities commonly used in oncology risk assessment and patient care

5 Indicate and implement personalized medicine approaches including surgical interventions, screening protocols, and systemic therapies appropriate for specific hereditary cancer predisposition syndromes/genes

|  |  |
| --- | --- |
|  |  |

**Accreditation:**

|  |  |
| --- | --- |
|  | In support of improving patient care, The University of Texas MD Anderson Cancer Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |

**Credit Designation**:

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 9.50 *AMA PRA Category 1* *Credits*TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 0.25 credit(s) of education in medical ethics and/or professional responsibility.

The University of Texas MD Anderson Cancer Center designates this live activity will award 9.50 Nursing Contact Hour(s)



**Disclosure of Financial Relationships:**

The University of Texas MD Anderson Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

**Faculty & Planner Disclosure:**

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Nature of Relationship(s) / Name of Ineligible Company(s)** |
| Felisha Estelle, BBA | Activity Administrator, Faculty | Nothing to disclose - 02/13/2025 |
| Linda T Hill | Other Planning Committee Member | Nothing to disclose - 09/16/2024 |
| Banu K Arun, MD, FASCO | Course Director, Faculty | Grant or research support-AstraZeneca US - 10/18/2024 |
| Molly Daniels, MS, CGC | Faculty | Nothing to disclose - 02/12/2025 |
| Courtney D. Dinardo, MD | Faculty, Other Planning Committee Member | Honoraria-AbbVie Inc.|Honoraria-Rigel|Honoraria-Daiichi Sankyo, Inc.|Honoraria-Gilead Sciences, Inc. (Relationship has ended)|Honoraria-Genentech, Inc.|Honoraria-Astellas Scientific and Medical Affairs, Inc. (Relationship has ended)|Honoraria-Bristol-Myers Squibb Company|Honoraria-GlaxoSmithKline|Honoraria-Jazz Pharmaceuticals|Honoraria-Novartis Pharmaceuticals Corporation (Relationship has ended)|Honoraria-Servier Pharmaceuticals|Honoraria-Immunogen (Relationship has ended)|Consulting Fee-Schrodinger|Advisor-Ellipses - 07/12/2024 |
| Walter Knowles, MBA | Other Planning Committee Member | Nothing to disclose - 10/21/2024 |
| Paul F Mansfield, MD | Faculty | Stocks or stock options, excluding diversified mutual funds-Amgen Inc.|Stocks or stock options, excluding diversified mutual funds-Stryker (any division) - 12/09/2024 |
| Ann H Molinaro, BSBM | Other Planning Committee Member | Nothing to disclose - 10/18/2024 |
| Julie Moskowitz, MS, CGC | Faculty | Nothing to disclose - 10/25/2024 |
| Donika Saporito, MS | Other Planning Committee Member | Consulting Fee-UpToDate - 12/02/2024 |
| Timothy A Yap, MD, PhD | Faculty | Grant or research support-Artios|Grant or research support-AstraZeneca US|Grant or research support-Bayer|Grant or research support-Beignene|Grant or research support-BioNtech|Grant or research support-Blueprint|Grant or research support-BMS|Grant or research support-Boundless Bio|Grant or research support-Clovis Oncology|Grant or research support-Constellation|Grant or research support-CPRIT,Cyteir|Grant or research support-Department of Defense,Eli Lilly|Grant or research support-EMD Serono Inc.|Grant or research support-Exelxis, Forbius|Grant or research support-F-Star|Grant or research support-GlaxoSmithKline|Grant or research support-Genentech, Inc.|Grant or research support-Gilead, Golfers against cancer, Haihe|Grant or research support-ImmuneSensor, Ideaya|Grant or research support-Ionis, Insilico Medicine|Grant or research support-Ipsen US|Grant or research support-Jounce|Grant or research support-Karyopharm Therapeutics|Grant or research support-KSQ|Grant or research support-Kyowa|Grant or research support-Merck, Mirati|Grant or research support-Novartis Pharmaceuticals Corporation|Grant or research support-Pfizer Inc.|Grant or research support-Pliant, Prelude, Ribon Therapeutics|Grant or research support-Regeneron Pharmaceuticals, Inc.|Grant or research support-Roche, Rubius|Grant or research support-Sanofi|Grant or research support-Scholar Rock, Synnovation|Grant or research support-Seattle Genetics, Inc.|Grant or research support-Tesaro, Tango|Grant or research support-V Foundation, Vivace, Zenith and Zentalis|Consulting Fee-AbbVie|Consulting Fee-Acrivon|Consulting Fee-Adagene, Almac, Aduro|Consulting Fee-Amgen Inc. |Consulting Fee-Amphista|Consulting Fee-Astex|Consulting Fee-Artios|Consulting Fee-AstraZeneca, Athena|Consulting Fee-Atrin|Consulting Fee-Avenzo, Avoro, Axiom|Consulting Fee-Bayer HealthCare Pharmaceuticals, Inc.|Consulting Fee-Bristol-Myers Squibb Company|Consulting Fee-Baptist Health Systems, Calithera, C4 Therapeutics|Consulting Fee-Clovis Oncology|Consulting Fee-Beigene, BioCity Pharma, Bloom Burton, Cybrexa|Consulting Fee-EMD Serono Inc.|Consulting Fee-Blueprint, Boxer, BridGene Biosciences|Consulting Fee-Cancer Research UK, Carrick Therapeutics, Circle Pharma|Consulting Fee-Cybrexa, Daiichi Sankyo, Dark Blue Therapeutics|Consulting Fee-Debiopharm, Diffusion, Duke Street Bio|Consulting Fee-858 Therapeutics, EcoR1 Capital, Ellipses Pharma|Consulting Fee-Entos, FoRx Therapeutics AG, F-Star|Consulting Fee-Genesis Therapeutics, Genmab, Glenmark|Consulting Fee-GLG, Globe Life Sciences, Grey Wolf Therapeutics |Consulting Fee-Pfizer Inc.|Consulting Fee-GSK, Guidepoint, Ideaya Biosciences, Idience|Consulting Fee-Ignyta, I-Mab, ImmuneSensor, Impact Therapeutics |Consulting Fee-Institut Gustave Roussy, Intellisphere, Jansen|Consulting Fee-Varian Medical Systems, Inc|Consulting Fee-Joint Sceientific Committee for Phase I Trials in HOng Kong|Consulting Fee-Kyn, Kyowa Kirin, Lumanity|Consulting Fee-MEI pharma, Mereo, Merck, Merit|Consulting Fee-Monte Rosa Therapeutics, Natera, Nested Therapeutics|Consulting Fee-Nexys, Nimbus, Novocure|Consulting Fee-Odyssey Therapeutics, OHSU, OncoSec|Consulting Fee-Ono Pharma, Onxeo, PanAngium Therapeutics|Consulting Fee-Pegascy, Per|Consulting Fee-Piper-Sandler, Pliant Therapeutics, Prelude Therapeutics|Consulting Fee-Prolynx, Protai Bio|Consulting Fee-Radiopharma, Synnovation, Synthis Therapeutics|Consulting Fee-Tango, TCG Crossover|Consulting Fee-TD2, Terremoto Biosciences|Consulting Fee-Tessellate Bio, Theragnostics, Terns Pharmaceuticals|Consulting Fee-Thryv Therapeutics, Tolremo, Tome|Consulting Fee-Trevarx Biomedical |Consulting Fee-Varian|Consulting Fee-veeva|Consulting Fee-versant, Viblome|Consulting Fee-Voronoi Inc.|Consulting Fee-Xinthera|Consulting Fee-Zai Labs|Consulting Fee-ZielBio|Stocks or stock options, excluding diversified mutual funds-Seagen - 01/31/2025 |
| Jessica Corredor, MS, CGC, Certified Genetic Counselor | Faculty | Nothing to disclose - 09/25/2024 |
| Marian Taylor, DNP, RN, CMSRN | Nurse Planner | Nothing to disclose - 02/20/2025 |
| Autumn Vara, MS | Other Planning Committee Member | Paid consultant-My Gene Counsel - 09/26/2024 |
| Jason A Willis, MD PhD | Faculty | Honoraria-Merck Sharp & Dohme Corp. (any division) (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-TME Therapeutics|Grant or research support-Nouscom - 02/10/2025 |
| Susan Reilly, MS, Certified Genetic Counselor | Co-Director, Faculty | Nothing to disclose - 11/22/2024 |
| Laurie McKenzie, Md  | Faculty | Other: Prior paid consultant, now research steering committee member-Springworks Pharmaceuticals - 02/24/2025 |
| Adrienne Ferrell, MSN | Faculty | Nothing to disclose - 09/17/2024 |
| Roni Wilke, MD | Faculty | Nothing to disclose - 09/17/2024 |
| Amitabha Palmer, PhD | Faculty | Nothing to disclose - 10/21/2024 |
| Andrew McKeon, Other, CGC | Faculty, Other Planning Committee Member | Nothing to disclose - 12/02/2024 |
| Hiam Abdel-Salam, Other | Faculty, Other Planning Committee Member | Nothing to disclose - 03/03/2025 |
| Rachael Shilbauer, MGCS | Other Planning Committee Member | Nothing to disclose - 11/22/2024 |
| Catherine Skefos, MS, CGC | Faculty | Nothing to disclose - 02/24/2025 |
| Marne Shafer | Faculty | Nothing to disclose - 03/14/2025 |
| Gabriela Chen, MS, MPH, CGC | Other Planning Committee Member | Nothing to disclose - 09/25/2024 |
| Susy Malca, MS, CGC | Faculty | Nothing to disclose - 01/14/2025 |
| Judy Calabria  | Faculty | Nothing to disclose - 03/13/2025 |
| Ashley Woodson, MS | Faculty | Nothing to disclose - 02/04/2025 |
| Tara R Buck, MD | Faculty | Nothing to disclose - 03/26/2025 |

**Notice:**

If this activity offers MOC, learner data (e.g., board member ID, first name, last name, DOB (MM/DD), CME credit data) will be shared with the ACCME and the applicable certifying boards.

**REQUIREMENTS FOR SUCCESSFUL ACTIVITY COMPLETION:**

To claim CE credits or contact hours for this activity, the participant must:

* **Have a profile in Professional Education Portal (PEP):**
1. Create an account and complete profile in (PEP).
2. Pair your email address to PEP (must use email address used to create PEP account). This is a **one-time** step in order to log your attendance using the text messaging feature in the future. Pairing your phone to the system is done by sending a **text** of your **email address** to **1-844-912-1333.**
* ​**Register** for and attend all sessions of this activity.
* ​**Record Attendance:** During the activity, the learner will TEXT the code: to **1-844-912-1333.** Learners have up to 24 hours after the activity has ended to text this code in order to record attendance.
* **​Evaluation:** Complete the participant evaluation in PEP within 30-days.
* **Claim Credit:** Claim your CE credits. Learners should claim only the credit commensurate with the extent of their participation in the activity.

**REQUIREMENTS TO EARN MOC POINTS (Physicians Only):**

* Complete the above requirements for successful activity completion.
* Click the MOC Test button.
* Complete your profile information (Specialty Board Diplomate ID and Date of Birth MM/DD) .
* Complete the MOC test. A passing score of 70% or higher is required. Unlimited attempts are allowed.

**Commercial Support:**

No commercial support has been received for this activity.